EPS for Conatus Pharmaceuticals Inc. (CNAT) Expected At $-0.13

October 14, 2018 - By Marie Mckinney

Investors sentiment decreased to 0.56 in Q2 2018. Its down 0.55, from 1.11 in 2018Q1. It worsened, as 23 investors sold Conatus Pharmaceuticals Inc. shares while 18 reduced holdings. 9 funds opened positions while 14 raised stakes. 9.33 million shares or 22.22% less from 11.99 million shares in 2018Q1 were reported.
Qs Invsts Lc holds 0% or 96,807 shares in its portfolio. D E Shaw & holds 66,506 shares. Moreover, Meeder Asset has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 1,130 shares. 36,823 are owned by Citigroup Inc. Moreover, Panagora Asset Mgmt Incorporated has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). New York-based Laurion Capital Mngmt L P has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Macquarie Grp Inc Limited invested in 7,700 shares. 125,749 are owned by Element Cap Mgmt Llc. State Street invested in 37,444 shares or 0% of the stock. Goldman Sachs Gp, a New York-based fund reported 418,995 shares. Vanguard Gp Inc owns 1.36M shares. Renaissance Technology Limited Liability Com has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Wells Fargo And Mn has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 27,306 shares. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 454 shares. Jpmorgan Chase & has 44,553 shares.

Analysts expect Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report $-0.13 EPS on November, 7.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.13 EPS. After having $-0.15 EPS previously, Conatus Pharmaceuticals Inc.’s analysts see -13.33 % EPS growth. The stock increased 3.54% or $0.17 during the last trading session, reaching $4.97. About 354,597 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has declined 18.52% since October 14, 2017 and is downtrending. It has underperformed by 34.14% the S&P500.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $149.95 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

More notable recent Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) news were published by: Seekingalpha.com which released: “Pfizer And Conatus: Emricasan And NASH” on September 19, 2018, also Globenewswire.com with their article: “Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting” published on October 02, 2018, Globenewswire.com published: “Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences” on September 19, 2018. More interesting news about Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) were released by: Seekingalpha.com and their article: “Conatus And Emricasan: The Moment” published on October 08, 2018 as well as Seekingalpha.com‘s news article titled: “Expected Value Investing: Diving Deeper On Conatus” with publication date: September 24, 2018.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>